Associated Papers
A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma.
Windon AL et al.
Journal of Gastrointestinal Oncology, 2018
Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
Custodio A et al.
Critical Reviews in Oncology/hematology, 2013
High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue.
Tol J et al.
Journal of Cellular and Molecular Medicine, 2010
Select a paper to view details